Effects of Ilozumab in the Treatment of Acute Myocardial Infarction After Percutaneous Coronary Intervention
OBJECTIVE:To explore the application value and safety of ilozumab combined with dual antiplatelet agents in patients with acute myocardial infarction(AMI)after percutaneous coronary intervention(PCI).METHODS:A total of 150 patients with AMI who received PCI in the hospital from 2020 to 2022 were extracted to be divided into the basic group and observation group according to different treatment methods,with 75 cases in each group.The basic group was given dual antiplatelet drug therapy(aspirin,clopidogrel),and the observation group received ilozumab therapy on the basis of the basic group.Cardiac function indicators,coronary blood flow grading and serum inflammatory factors were compared between two groups.All patients were followed up for 6 months,and the rate of vascular re-occlusion and total incidence of major adverse cardiovascular events(MACE)were compared between two groups.RESULTS:After treatment,the left ventricular end-systolic diameter of observation group was lower than that of basic group,and the left ventricular ejection fraction of observation group was higher than that of basic group,with statistically significant difference(P<0.05).After treatment,the coronary blood flow grading of observation group was better than that of basic group,with statistically significant difference(P<0.05).After treatment,the serum levels of interleukin-6,hypersensitive C-reactive protein and tumor necrosis factor-α in observation group were lower than those in basic group,with statistically significant difference(P<0.05).The rate of vascular re-occlusion within 6 months in the observation group was 1.33%(1/75),lower than 10.67%(8/75)in the basic group;the total incidence of MACE in observation group was 2.67%(2/75),lower than 12.00%(9/75)in basic group,the differences were statistically significant(P<0.05).CONCLUSIONS:Ilouzumab combined with dual antiplatelet drugs(aspirin and clopidogrel)can effectively improve cardiac function and coronary microcirculation in AMI patients after PCI,reduce inflammatory response,and decrease the rate of vascular re-occlusion and incidence of MACE,with significant efficacy.
万方数据
维普
